Neville Rodie & Shaw’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$22.4M Sell
88,895
-17,684
-17% -$3.8M 1.45% 17
2026
Q1
$23.2M Buy
106,579
+4,570
+4% +$1.01M 1.68% 15
2025
Q4
$23.3M Buy
102,009
+18,004
+21% +$4.1M 1.65% 16
2025
Q3
$19.5M Sell
84,005
-175
-0.2% -$35.6K 1.41% 19
2025
Q2
$15.6M Sell
84,180
-7,335
-8% -$1.36M 1.16% 24
2025
Q1
$19.2M Sell
91,515
-5,115
-5% -$994K 1.5% 18
2024
Q4
$17.2M Sell
96,630
-4,285
-4% -$788K 1.25% 22
2024
Q3
$19.9M Buy
100,915
+5,172
+5% +$965K 1.47% 20
2024
Q2
$16.4M Buy
95,743
+762
+0.8% +$126K 1.25% 22
2024
Q1
$17.3M Sell
94,981
-1,288
-1% -$222K 1.32% 21
2023
Q4
$14.9M Sell
96,269
-1,651
-2% -$241K 1.22% 22
2023
Q3
$14.6M Sell
97,920
-2,000
-2% -$294K 1.3% 22
2023
Q2
$13.5M Sell
99,920
-21,820
-18% -$3.2M 1.16% 24
2023
Q1
$19.4M Sell
121,740
-895
-0.7% -$137K 1.76% 13
2022
Q4
$19.8M Sell
122,635
-476
-0.4% -$73K 1.86% 11
2022
Q3
$16.5M Sell
123,111
-517
-0.4% -$74.2K 1.62% 15
2022
Q2
$18.9M Sell
123,628
-2,086
-2% -$319K 1.7% 12
2022
Q1
$20.5M Sell
125,714
-193
-0.2% -$28K 1.52% 17
2021
Q4
$17M Sell
125,907
-990
-0.8% -$117K 1.21% 26
2021
Q3
$13.7M Sell
126,897
-475
-0.4% -$54.3K 1.06% 31
2021
Q2
$14.3M Sell
127,372
-392
-0.3% -$44.1K 1.11% 29
2021
Q1
$13.8M Sell
127,764
-2,424
-2% -$259K 1.15% 29
2020
Q4
$13.9M Sell
130,188
-5,758
-4% -$553K 1.21% 25
2020
Q3
$11.9M Buy
135,946
+8,320
+7% +$783K 1.12% 27
2020
Q2
$12.5M Buy
127,626
+30,307
+31% +$2.67M 1.29% 21
2020
Q1
$7.42M Buy
97,319
+11,575
+13% +$986K 0.9% 37
2019
Q4
$7.59M Sell
85,744
-75
-0.1% -$6.23K 0.74% 44
2019
Q3
$6.5M Sell
85,819
-2,400
-3% -$165K 0.69% 46
2019
Q2
$6.42M Sell
88,219
-10,734
-11% -$844K 0.68% 48
2019
Q1
$7.97M Sell
98,953
-11,206
-10% -$917K 0.85% 35
2018
Q4
$10.2M Sell
110,159
-1,950
-2% -$171K 1.23% 21
2018
Q3
$10.6M Sell
112,109
-2,341
-2% -$222K 1.05% 28
2018
Q2
$10.6M Sell
114,450
-4,570
-4% -$446K 1.12% 25
2018
Q1
$11.3M Sell
119,020
-2,553
-2% -$280K 1.24% 22
2017
Q4
$11.8M Sell
121,573
-4,650
-4% -$438K 1.24% 24
2017
Q3
$11.2M Sell
126,223
-2,975
-2% -$226K 1.25% 23
2017
Q2
$9.37M Sell
129,198
-14,630
-10% -$984K 1.07% 30
2017
Q1
$9.37M Sell
143,828
-30,431
-17% -$1.91M 1.07% 29
2016
Q4
$10.9M Sell
174,259
-8,550
-5% -$522K 1.29% 20
2016
Q3
$11.5M Sell
182,809
-2,627
-1% -$170K 1.36% 17
2016
Q2
$11.5M Sell
185,436
-8,110
-4% -$494K 1.38% 12
2016
Q1
$11.1M Sell
193,546
-8,411
-4% -$469K 1.34% 16
2015
Q4
$12M Sell
201,957
-12,086
-6% -$696K 1.44% 14
2015
Q3
$11.6M Buy
214,043
+21,550
+11% +$1.4M 1.43% 16
2015
Q2
$12.9M Buy
192,493
+24,931
+15% +$1.63M 1.42% 15
2015
Q1
$9.81M Sell
167,562
-4,969
-3% -$300K 1.02% 26
2014
Q4
$11.3M Buy
172,531
+21,225
+14% +$1.34M 1.14% 24
2014
Q3
$8.74M Buy
151,306
+75,143
+99% +$4.17M 0.86% 34
2014
Q2
$4.3M Buy
76,163
+9,948
+15% +$522K 0.43% 70
2014
Q1
$3.4M Sell
66,215
-1,675
-2% -$84.7K 0.37% 74
2013
Q4
$3.58M Buy
67,890
+4,846
+8% +$238K 0.39% 72
2013
Q3
$2.82M Sell
63,044
-1,500
-2% -$66.5K 0.33% 78
2013
Q2
$2.67M Buy
+64,544
New +$2.82M 0.32% 78

Other funds holding ABBV

Neville Rodie & Shaw's ABBV Position: Q2 2026 in Review

Neville Rodie & Shaw reduced its AbbVie (ABBV) stake by 17% in Q2 2026, selling an estimated $3.8M and leaving 88,895 shares worth $22.4M. The position accounts for 1.45% of the portfolio, ranked #17.

Neville Rodie & Shaw first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. The position peaked at $23.3M in Q4 2025. 1,743 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Neville Rodie & Shaw held 88,895 shares of AbbVie worth $22.4M as of Q2 2026.
  • Neville Rodie & Shaw sold 17,684 AbbVie shares in Q2 2026, an estimated $3.8M.
  • AbbVie made up 1.45% of Neville Rodie & Shaw's portfolio in Q2 2026, its #17 holding.
  • Neville Rodie & Shaw first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
  • Neville Rodie & Shaw's AbbVie position peaked at $23.3M in Q4 2025.
  • 1,743 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Neville Rodie & Shaw's 13F filing for Q2 2026, filed 6 Jul 2026.